Outcome and Proceedings of the 2nd Extraordinary General Meeting for F.Y. 2026-27, scheduled to be held on 31st July, 2026, at 12:30 P.M. through Video Conferencing and Other Audio-Visual Means.

ASSTON PHARMACEUTICALS LIMITED (FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED) Date: 31.07.2026 BSE Limited (BSE Ltd) Listing / Compliance Department, Dalal Street, Mumbai – 400001 BSE Scrip Code: 54445 Subject: Outcome and Proceedings of the Extraordinary General Meeting of Asston Pharmaceuticals Limited held on 31.07.2026 Dear Sir/Madam, Pursuant to Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), we enclose herewith the outcome and proceedings of the Extraordinary General Meeting of Asston Pharmaceuticals Limited held on Friday, 31st July, 2026 at 12.30 P.M. through Video Conferencing (VC) facility /Other Audio Visual Means (“OAVM”). You are requested to please take note of the same in your record. Thanking you For and on behalf of the Board of Directors Rishi Upadhaya Company Secretary and Compliance Officer A74324 Date: 31-07-2026 Place: Mumbai Encl: Attached CIN: U24304MH2019PLC324187 Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com Web: www.asstonpharmaceuticals.com ASSTON PHARMACEUTICALS LIMITED (FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED) Summary of proceedings of the Extraordinary General Meeting The 2nd Extraordinary General Meeting for F.Y. 2026-27 (‘EGM’ or ‘Meeting’) of the Shareholders of Asston Pharmaceuticals Limited (‘the Company’) was held on Friday, 31st July, 2026 at 12:30 P.M. via Video Conferencing facility /Other Audio Visual Means. Name of Person Designation DIRECTOR(S) PRESENT Mr. Ashish Narayan Sakalkar Managing Director Mrs. Saili Jayaram More Whole Time Director and CEO Mr. Rishabh Kumar Jain Independent Director Mr. Sachin Chandrakant Badakh Non- Executive Director Mr. Sandip Sharma Independent Director Mrs. Vijaya E Shahapurkar Independent Director Mr. Yashvardhan Nitin Tupe Non- Executive Director Mr. Yogesh Prakesh Supekar Non- Executive Director KMP PRESENT Mr. Rishi Upadhaya Company Secretary (“CS”) Mr. Sumit Dattatray Pawar Chief Financial Officer (“CFO”) AUDITOR & SCRUTINIZER PRESENT M/s Panchal SK and Associates Statutory Auditor Miss. Pragya Jain Scrutinizer The 2nd Extraordinary General Meeting for F.Y. 2026-27 of the Shareholders of Asston Pharmaceuticals Limited was held on 31st July, 2026 at 12:30 P.M. via Video Conferencing facility/Other Audio Visual Means. The Company, while conducting the Meeting, adhered to the circulars issued by the Ministry of Corporate Affairs (‘MCA’), the Securities and Exchange Board of India (‘SEBI’) Mr. Rishi Upadhaya, Company Secretary & Compliance Officer of the Company, welcomed all the members, directors, and invitees attending the Extraordinary General Meeting of the Company through Video Conferencing/Other Audio-Visual Means. The Company Secretary requested Mr. Ashish Narayan Sakalkar to occupy the Chair & act as the Chairman for the meeting with the permission of the members. Mr. Ashish Narayan Sakalkar welcomed the Members to the Meeting, and the Company Secretary briefed them on certain points relating to the participation at the Meeting through VC. The meeting was held through video conferencing mode without the physical presence of the members at the common venue in accordance with the circulars issued by the Ministry of Corporate Affairs. The Company has taken all feasible steps to ensure that the shareholders are provided an opportunity to participate in the Extraordinary General Meeting and to vote on all the resolutions as mentioned in CIN: U24304MH2019PLC324187 Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com Web: www.asstonpharmaceuticals.com ASSTON PHARMACEUTICALS LIMITED (FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED) the EGM Notice. An adequate audio-video conferencing facility for this meeting has also been provided. Mr. Ashish Narayan Sakalkar, Chairman of the Meeting, chaired the Proceedings of the Meeting. The requisite quorum was present; the meeting was called to order with the permission of the Chairman. The Registers as required under the Companies Act, 2013, and other relevant documents mentioned in the Notice were available for inspection. Since there was no physical attendance of Members and in compliance with the Circulars issued by MCA and SEBI, the requirement of appointing proxies was not applicable, except for the authorized representatives of corporate shareholders. With the consent of the Members, the resolutions as set out in the Notice of the Extraordinary General Meeting were taken as read. The Company Secretary informed the Members that the Company had provided its members with the facility to cast their vote electronically through the NSDL system before the Meeting. He further informed that the remote e-voting facility was also made available from 28th July, 2026 at 9.00 A.M. and concluded on 30th July, 2026 at 5:00 P.M. and the members who have not exercised their voting rights during remote e-voting period can still cast their votes on all the resolutions as outlined in the notice of EGM through instant Voting facilities provided by NSDL during the EGM for the benefit of Members who were present during the Meeting and had not cast their votes earlier through remote e-voting. The Company Secretary explained the Shareholders' resolutions proposed to be passed at this EGM. He informed the shareholders that the window for electronic voting shall remain open till 15 minutes post the conclusion of the EGM and requested members to vote. The Company Secretary informed that Ms. Pragya Jain, Practicing Company Secretary, had been appointed by the Board as the Scrutinizer to scrutinize the votes cast during the Meeting and through remote e-voting fairly and transparently. The Voting Results shall be declared, along with the Scrutinizer's Report, and shall be placed on the website of the Company and also on the BSE Limited, within 2 working days from the conclusion of this EGM. The following resolutions set out in the Notice convening the EGM were put to a vote by remote e- voting from 28th July, 2026, at 09:00 A.M. and concluded on 30th July, 2026 at 5:00 P.M., and remote e-voting during the Meeting: - Item Details of the Agenda Business Mode of Voting No. (Ordinary / Special) CIN: U24304MH2019PLC324187 Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi Mumbai, Thane, Maharashtra, 400614, India Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com Web: www.asstonpharmaceuticals.com ASSTON PHARMACEUTICALS LIMITED (FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED) 1. To issue equity shares on preferential basis. Special Remote e-voting and e-voting during the EGM Mr. Rishi Upadhaya informed the shareholders during the Extraordinary General Meeting of the company that the company has received 0 (Zero) emails from any shareholders to get them registered as speakers for this Extraordinary General Meeting. The questions, if any, received by the company have already been answered by the company to the concerned shareholder at their registered email. The Scrutinizer is authorized to carry out the voting process after this meeting. The combined results of the remote e-voting as well as Instant remote e-voting during the EGM would be announced within 2 working days of the conclusion of the Meeting, and the results, along with the Scrutinizer's Report, would be intimated to the Stock Exchanges in terms of the Listing Regulations and would be placed on the websites of the Company and NSDL. The Company Secret [Showing first 8,000 characters — download PDF for full document]